Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rosuvastatin efficacy and 2-year safety study in children and adolescents with familial hypercholesterolaemia
2009-016492-29Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of rosuvastatin in familial hypercholesterolemia (FH) (4 arms), sponsored by AstraZeneca. Primary endpoints: Percentage reduction in LDL-C from baseline to 3 months, Percentage reduction in LDL-C from baseline to 12 months and 1 more. Started Dec 2009; status: completed.
02
Drugs
rosuvastatin
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2009-016492-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016492-29.